CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
30 cc bolus of a low osmolar, iodinated CT contrast agent, which is FDA approved and used in
the clinical CT Imaging procedure.
The 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI) is FDA
approved for clinical CT imaging
Research Design and Methods
1) Primary Endpoint
1. Diagnostic yield of tumor perfusion measurements using a contrast assisted computed
2) Secondary Endpoints
1. Reproducibility of tumor blood flow estimates derived by CT.
2. Assessment of the association between tumor vascularity responses after two cycles of
chemotherapy and subsequent best tumor response according to standard anatomic response
evaluation criteria (RECIST).
3. Predictive value of tumor blood flow for patient survival, compared to the predictive
power of tumor size determinations.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Diagnostic yield of tumor perfusion measurements using a contrast assisted computed tomography technique.
Data collected during one required study visit, and optional second study visit ~6-8 weeks later.
Mark A. Socinski, MD
University of Pittsburgh
United States: Institutional Review Board
|University of Pittsburgh Cancer Institute||Pittsburgh, Pennsylvania 15213|
|University of Pittsburgh Cancer Institute - Hillman Cancer Center||Pittsburgh, Pennsylvania 15232|
|Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology||Pittsburgh, Pennsylvania 15232|